Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+1-450-6872262
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Neptune Technologies & Bioressources (CVE:NTB) Frequently Asked Questions
What is Neptune Technologies & Bioressources' stock symbol?
Neptune Technologies & Bioressources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."
How were Neptune Technologies & Bioressources' earnings last quarter?
Neptune Technologies & Bioressources Inc (CVE:NTB) announced its quarterly earnings results on Tuesday, July, 15th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The biotechnology company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million. View Neptune Technologies & Bioressources' Earnings History.
Has Neptune Technologies & Bioressources been receiving favorable news coverage?
Media headlines about NTB stock have been trending positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neptune Technologies & Bioressources earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the next several days.
What other stocks do shareholders of Neptune Technologies & Bioressources own?
Who are Neptune Technologies & Bioressources' key executives?
Neptune Technologies & Bioressources' management team includes the folowing people:
- John Moretz, Chairman of the Board
- James Stuart Hamilton, President, Chief Executive Officer, Director
- Mario Paradis, Chief Financial Officer
- Michel Timperio, Senior Vice President of Sales - Global Sales
- Pierre Lemieux Ph.D., Chief Operating Officer of Acasti
- Jean-Daniel Belanger, Corporate Secretary and Director - Corporate Affairs
- Harlan W. Waksal M.D., Director (Age 61)
- Valier Boivin, Independent Director
- Ronald Denis, Independent Director
- Adrian Taylor Montgomery, Independent Director
How do I buy shares of Neptune Technologies & Bioressources?
Shares of NTB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Neptune Technologies & Bioressources' official website?
How can I contact Neptune Technologies & Bioressources?
Neptune Technologies & Bioressources' mailing address is 545 Prom du Centropolis Suite 100, LAVAL, QC H7T 0A3, Canada. The biotechnology company can be reached via phone at +1-450-6872262.
MarketBeat Community Rating for Neptune Technologies & Bioressources (CVE NTB)
MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe NTB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTB will underperform the S&P 500 over the long term. You may vote once every thirty days.
